CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Dimerix Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Dimerix Ltd
425 Smith Street, Fitzroy
Phone: +61 300813321p:+61 300813321 MELBOURNE, VIC  3065  Australia Ticker: DXBDXB

Business Summary
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing new therapies in areas with unmet medical needs for global markets. It is focused on developing its products, DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its DMX-200 and DMX-700 are identified using its assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. It has completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease. Receptor-HIT is licensed to Excellerate Bioscience.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20236/30/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board MarkDiamond 12/1/2023 12/1/2023
Chief Executive Officer, Managing Director, Director NinaWebster 1/1/2021 8/27/2018
Chief Financial Officer, Company Secretary HamishGeorge 5/6/2019 5/6/2019
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Dimerix Bioscience Pty Ltd L 11 63 Exhibition Street Melbourne VIC Australia

Business Names
Business Name
Dimerix Bioscience Ltd
DXB
DXBDC
Harrington Group Limited
Sun Biomedical Laboratories Inc.
Sun Biomedical Limited

General Information
Outstanding Shares: 426,177,054 (As of 12/31/2023)
Shareholders: 4,991
Stock Exchange: ASX
Fax Number: +61 893888256


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, March 18, 2024